Rekvina Laboratories (BOM:526075) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Rekvina Laboratories Debt-to-Equity?

Rekvina Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Rekvina Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Rekvina Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rekvina Laboratories's Debt-to-Equity or its related term are showing as below:

BOM:526075' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.31 Max: 6.17
Current: 26.26

During the past 13 years, the highest Debt-to-Equity Ratio of Rekvina Laboratories was 6.17. The lowest was 0.02. And the median was 0.31.

BOM:526075's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs BOM:526075: 26.26

Rekvina Laboratories Debt-to-Equity Historical Data

The historical data trend for Rekvina Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rekvina Laboratories Debt-to-Equity Chart

Rekvina Laboratories Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.51

N/A

6.17

Rekvina Laboratories Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	6.17	N/A	-	N/A

Competitive Comparison of Rekvina Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Rekvina Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rekvina Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rekvina Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rekvina Laboratories's Debt-to-Equity falls into.

Rekvina Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rekvina Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.814	+	0)	/	0.132
	=	6.17

Rekvina Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Rekvina Laboratories (BOM:526075) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rekvina Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rekvina Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rekvina Laboratories (BOM:526075) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rekvina Laboratories Ltd (BOM:526075) » Definitions » Debt-to-Equity

Comparable Companies

BOM:524516 BOM:531686 EAPH BOM:531521 BOM:524322 XPAR:MLGML TLGTQ BOM:524604 MJARF BOM:532041

Traded in Other Exchanges

N/A

Address

328, Paradise Complex, Sayajigunj Baroda, Vadodara, GJ, IND, 390005

Website

https://www.rekvinalaboratories.com

Rekvina Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical formulations. The company also has dispersible kid tablets for pediatric patients. The pharmaceutical products of the company include REKFA, an essential fatty acid in the capsule, and REKSEAL, the tissue adhesive.

Rekvina Laboratories (BOM:526075) Headlines

No Headlines